Design Therapeutics Statistics
Total Valuation
DSGN has a market cap or net worth of $221.66 million. The enterprise value is -$4.17 million.
Important Dates
The last earnings date was Monday, March 10, 2025, before market open.
| Earnings Date | Mar 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DSGN has 56.76 million shares outstanding. The number of shares has increased by 1.08% in one year.
| Current Share Class | 56.76M |
| Shares Outstanding | 56.76M |
| Shares Change (YoY) | +1.08% |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | 15.57% |
| Owned by Institutions (%) | 40.14% |
| Float | 25.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.99 |
| P/TBV Ratio | 0.99 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 29.31, with a Debt / Equity ratio of 0.01.
| Current Ratio | 29.31 |
| Quick Ratio | 29.16 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -19.08% and return on invested capital (ROIC) is -14.85%.
| Return on Equity (ROE) | -19.08% |
| Return on Assets (ROA) | -14.39% |
| Return on Invested Capital (ROIC) | -14.85% |
| Return on Capital Employed (ROCE) | -25.61% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$918,296 |
| Employee Count | 54 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +7.67% in the last 52 weeks. The beta is 1.78, so DSGN's price volatility has been higher than the market average.
| Beta (5Y) | 1.78 |
| 52-Week Price Change | +7.67% |
| 50-Day Moving Average | 4.71 |
| 200-Day Moving Average | 5.00 |
| Relative Strength Index (RSI) | 40.65 |
| Average Volume (20 Days) | 156,420 |
Short Selling Information
The latest short interest is 3.27 million, so 5.76% of the outstanding shares have been sold short.
| Short Interest | 3.27M |
| Short Previous Month | 3.22M |
| Short % of Shares Out | 5.76% |
| Short % of Float | 12.87% |
| Short Ratio (days to cover) | 16.97 |
Income Statement
| Revenue | n/a |
| Gross Profit | -44.35M |
| Operating Income | -62.38M |
| Pretax Income | -50.53M |
| Net Income | -49.59M |
| EBITDA | -61.79M |
| EBIT | -62.38M |
| Earnings Per Share (EPS) | -$0.88 |
Full Income StatementBalance Sheet
The company has $245.48 million in cash and $2.33 million in debt, giving a net cash position of $243.14 million or $4.28 per share.
| Cash & Cash Equivalents | 245.48M |
| Total Debt | 2.33M |
| Net Cash | 243.14M |
| Net Cash Per Share | $4.28 |
| Equity (Book Value) | 242.10M |
| Book Value Per Share | 4.27 |
| Working Capital | 239.58M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$43.11 million and capital expenditures -$340,000, giving a free cash flow of -$43.45 million.
| Operating Cash Flow | -43.11M |
| Capital Expenditures | -340,000 |
| Free Cash Flow | -43.45M |
| FCF Per Share | -$0.77 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |